Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25379847 | 0.81 | TRPV1 (0.46) | ABCG2TRPV1EPHX2PDE10A | |
| SCHEMBL25376142 | 0.81 | EPHX2 (0.45) | ABCG2TRPV1EPHX2 | |
| SCHEMBL25376256 | 0.80 | KCNQ3 (0.48) | TRPV1EPHX2PDE10APIK3CATP53 | |
| SCHEMBL25377412 | 0.79 | PDE10A (0.54) | PDE10A | |
| SCHEMBL25956364 | 0.77 | TRPV1 (0.45) | ABCG2TRPV1EPHX2PIK3CA | |
| SCHEMBL25375889 | 0.77 | EPHX2 (0.44) | TRPV1EPHX2 | |
| SCHEMBL25379729 | 0.77 | GRM5 (0.37) | PDE10A | |
| SCHEMBL25340468 | 0.76 | TRPV1 (0.49) | TRPV1EPHX2 | |
| SCHEMBL25974052 | 0.76 | TRPV1 (0.44) | ABCG2TRPV1EPHX2 | |
| SCHEMBL30482552 | 0.75 | EGFR (0.47) | ABCG2TRPV1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146512-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146512-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |